Cell death pathways in response to antitumor therapy

Area of Science:

• Oncology
• Molecular Biology
• Cell Death Research

Background:

• Antitumor therapies aim to eliminate cancer cells, often by inducing apoptosis (programmed cell death).
• Resistance to cancer drugs can arise from cancer cells' ability to evade apoptosis.
• Mutations in tumor suppressor genes like p53 are common in cancer and can affect drug sensitivity.

Purpose of the Study:

• To critically review the diverse cell death pathways elicited by antitumor therapy in human cancers.
• To explore how cancer cells respond to cytotoxic agents through mechanisms beyond apoptosis.
• To understand the implications of various cell death modalities for antitumor drug resistance.

Main Methods:

• Literature review of studies on cancer cell death mechanisms induced by antitumor agents.
• Analysis of research on apoptosis, mitotic catastrophe, necrosis, autophagy, and senescence in cancer therapy.
• Examination of the role of genetic mutations, such as in p53, in modulating cell death responses.

Main Results:

• Antitumor therapy can induce multiple forms of cell death, including apoptosis, mitotic catastrophe, necrosis, autophagy, and senescence.
• Mitotic catastrophe, a death pathway from abnormal cell division, may not require functional p53.
• Cancer cells' evasion of these diverse death pathways contributes to drug resistance.

Conclusions:

• Understanding the spectrum of cell death pathways is crucial for developing effective cancer treatments.
• Targeting multiple cell death mechanisms may overcome or prevent drug resistance in cancer.
• The interplay between genetic mutations and cell death pathways significantly impacts cancer therapy efficacy.